Biopsies reveal breadth of drug’s kidney protection

A recent clinical study conducted by the University of Washington School of Medicine provides new insights into kidney protection for youth living with type 1 diabetes. Researchers examined the effects of dapagliflozin, an SGLT2 inhibitor, on 98 participants between the ages of 12 and 21. By analyzing kidney biopsies before and after the 16-week treatment period, the team identified significant molecular shifts within the tissue.

The study revealed that the medication corrected abnormal biological processes associated with early kidney damage. Key improvements included reduced inflammation, healthier energy use in cells, and better oxygen balance. In fact, over 55% of the genes affected by the treatment moved toward patterns observed in healthy kidney tissue. This indicates that the drug may help reset the kidney to a more functional state rather than simply masking symptoms.

Dr. Petter Bjornstad, the corresponding author and professor of pediatrics and medicine, noted that the research looked directly at cellular behavior rather than relying solely on blood or urine tests. The findings showed a coordinated response throughout the entire kidney, affecting not just sugar-handling cells but also blood vessel linings and filters. This mapping of molecular signatures provides a roadmap for developing future therapies that target these specific pathways.

These results offer a promising shift in how medical professionals approach diabetic kidney disease. Currently, approximately one-third of people with type 1 diabetes develop chronic kidney disease, often without early detection. This research suggests that treating the condition early, potentially during adolescence or young adulthood, could prevent long-term damage before it becomes detectable through standard diagnostic methods. Larger trials are currently investigating the long-term impact of this approach.